Eureka Therapeutics to Present at the CAR-TCR Summit Europe
Emeryville, California, February 18, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Emeryville, California, February 18, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Emeryville, California, December 3, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced that new
Emeryville, California, October 31, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced the presentation
– POTENTIAL TO ACCELERATE APPLICATION OF T-CELL THERAPY TO OTHER SOLID TUMORS Emeryville, California, August 5, 2019 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical
– POTENTIAL TO IMPROVE EFFICACY OF T-CELL AND IMMUNE CHECKPOINT BLOCKADE THERAPIES IN SOLID TUMORS Emeryville, California, April 15, 2019 – Eureka Therapeutics, Inc., a clinical
– POTENTIAL TO TARGET GPRC5D IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER BCMA-TARGETED THERAPY Emeryville, California, March 27, 2019 – Eureka Therapeutics, Inc., a clinical stage
EMERYVILLE, California, February 11, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced the appointment of Hanzhong
EMERYVILLE, California, January 30, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced that the U.S. Food
–NEW DATA FROM MULTIPLE CAR-T PROGRAMS IN MULTIPLE MYELOMA UTILIZING EUREKA’S BINDING DOMAINS –BCMA/MULTIPLE MYELOMA CAR-T PROGRAM LICENSED TO JUNO THERAPEUTICS (NOW CELGENE) –UPDATED DATA
EMERYVILLE, California, November 21, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies
We use cookies and similar technologies to operate the website and, if you allow it, to measure traffic and improve performance. You can accept or reject non-essential cookies. Necessary cookies remain active because the site cannot work properly without them. Privacy Policy and Do Not Sell or Share My Personal Information .
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.
